Physician profile
Brandy B Ma
NPI 1891130092
$6,586.63
in general payments reported to CMS, 2019-2025
26 companies · $2,043 in 2025
The $2,043 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20.45 · 2020: $546 · 2021: $329 · 2022: $454 · 2023: $1,062 · 2024: $2,132 · 2025: $2,043.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,837 · Consulting Fee: $400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,837.23 |
| Consulting Fee | $400.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $2,237.21 | 2020-2025 | Xcopri |
| Ucb, INC. | $1,598.68 | 2020-2025 | Fintepla, Briviact, Nayzilam |
| Jazz Pharmaceuticals INC. | $706.84 | 2022-2025 | Epidiolex |
| Monteris Medical Corporation | $580.51 | 2020-2024 | Neuroblate |
| Neuropace, INC. | $491.24 | 2020-2025 | |
| Aucta Pharmaceuticals, INC. | $117.04 | 2024-2025 | Motpoly Xr |
| Eisai INC. | $97.43 | 2019-2023 | |
| Neurelis, INC. | $95.89 | 2021 | |
| Livanova USA, INC. | $72.62 | 2021 | |
| Catalyst Pharmaceuticals, INC. | $70.31 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $62.68 | 2023-2024 | Aptiom |
| Otsuka America Pharmaceutical, INC. | $53.12 | 2023 | Nuedexta |
| Amgen INC. | $50.87 | 2022-2023 | Repatha |
| Greenwich Biosciences, INC. | $50.02 | 2020-2021 | |
| Owp Pharmaceuticals, INC. | $35.47 | 2023-2025 | Subvenite, Lamotrigine |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aquestive Therapeutics, INC. | $34.56 | 2020-2022 | |
| Immedica Pharma US, INC. | $33.21 | 2023 | |
| Janssen Pharmaceuticals, INC | $30.39 | 2021-2024 | Xarelto |
| Astrazeneca Pharmaceuticals Lp | $27.28 | 2022-2023 | Andexxa |
| Amylyx Pharmaceuticals, INC. | $25.60 | 2023 | Relyvrio |
| Csl Behring | $24.57 | 2023 | Kcentra |
| Lundbeck LLC | $19.63 | 2022 | |
| Grifols USA, LLC | $18.38 | 2024 | Gamunex-C |
| Genentech, INC. | $18.29 | 2021 | |
| Sunovion Pharmaceuticals INC. | $17.71 | 2022 | |
| Grt US Holding, INC. | $17.08 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandy Ma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.